Free Trial
Your Portfolio Deserves Better! MarketBeat All Access for Just $149
Upgrade Now
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyanotech Co. stock logo
CYAN
Cyanotech
$0.52
0.0%
$0.37
$0.21
$0.57
$3.84M0.177,595 shs460 shs
JAN stock logo
JAN
JAN
$26.58
-0.7%
$25.16
$22.76
$28.52
$6.99B2.16961,106 shs179,160 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$121.87
+5.2%
$115.79
$75.40
$125.14
$300.65B0.1810.83 million shs7.84 million shs
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
$1.07
-0.9%
$1.15
$0.88
$32.16
$4.18M-0.14440,275 shs8,062 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00%-5.45%+38.26%+30.00%+48.57%
JAN stock logo
JAN
JAN
+0.06%-0.74%+8.68%+262.45%+262.45%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.52%+2.34%+2.87%-5.07%+50.68%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-0.92%+4.85%-6.90%-23.94%-96.50%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cyanotech Co. stock logo
CYAN
Cyanotech
$0.52
0.0%
$0.37
$0.21
$0.57
$3.84M0.177,595 shs460 shs
JAN stock logo
JAN
JAN
$26.58
-0.7%
$25.16
$22.76
$28.52
$6.99B2.16961,106 shs179,160 shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$121.87
+5.2%
$115.79
$75.40
$125.14
$300.65B0.1810.83 million shs7.84 million shs
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
$1.07
-0.9%
$1.15
$0.88
$32.16
$4.18M-0.14440,275 shs8,062 shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00%-5.45%+38.26%+30.00%+48.57%
JAN stock logo
JAN
JAN
+0.06%-0.74%+8.68%+262.45%+262.45%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
+2.52%+2.34%+2.87%-5.07%+50.68%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-0.92%+4.85%-6.90%-23.94%-96.50%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cyanotech Co. stock logo
CYAN
Cyanotech
0.00
N/AN/AN/A
JAN stock logo
JAN
JAN
2.83
Moderate Buy$27.915.02% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.68
Moderate Buy$128.185.17% Upside
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest JAN, MRK, REVB, and CYAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
DowngradeHold (C+)Hold (C)
5/13/2026
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
DowngradeSell (E+)Sell (E)
5/13/2026
JAN stock logo
JAN
JAN
Boost Price TargetOverweight$26.00 ➝ $30.00
5/8/2026
JAN stock logo
JAN
JAN
Boost Price TargetOutperform$27.00 ➝ $30.00
5/6/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Initiated CoverageNeutral$125.00
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Reiterated RatingHold (C+)
5/1/2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Lower Price TargetOverweight$150.00 ➝ $145.00
4/27/2026
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
UpgradeSell (E)Sell (E+)
4/15/2026
JAN stock logo
JAN
JAN
UpgradeHold
4/14/2026
JAN stock logo
JAN
JAN
Initiated CoverageNeutral$27.00
4/14/2026
JAN stock logo
JAN
JAN
Initiated CoverageOutperform$27.00
(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cyanotech Co. stock logo
CYAN
Cyanotech
$24.22M0.16N/AN/A$1.23 per share0.42
JAN stock logo
JAN
JAN
$822.58M8.50N/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$65.01B4.63$12.32 per share9.89$18.60 per share6.55
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/A$3.32 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cyanotech Co. stock logo
CYAN
Cyanotech
-$3.20M-$0.25N/AN/AN/A-7.03%-20.62%-7.52%N/A
JAN stock logo
JAN
JAN
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$18.25B$3.5534.2912.462.5413.59%27.55%10.73%8/4/2026 (Estimated)
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$8.91M-$39.48N/AN/AN/AN/A-107.65%-87.98%8/7/2026 (Estimated)

Latest JAN, MRK, REVB, and CYAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2026Q1 2026
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$1.15-$2.71-$1.56-$2.71N/AN/A
5/5/2026Q1 2026
JAN stock logo
JAN
JAN
$0.23$0.23N/A$0.23$157.96 million$200.35 million
4/30/2026Q1 2026
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$1.47-$1.28+$0.19-$1.72$15.85 billion$16.29 billion
2/26/2026Q4 2025
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
-$1.41-$1.65-$0.24-$1.65N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cyanotech Co. stock logo
CYAN
Cyanotech
N/AN/AN/AN/AN/A
JAN stock logo
JAN
JAN
$0.642.41%N/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.402.79%+5.75%95.77%14 Years
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/AN/AN/AN/AN/A

Latest JAN, MRK, REVB, and CYAN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/7/2026
JAN stock logo
JAN
JAN
quarterly$0.15992.26%6/12/20266/12/20266/24/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cyanotech Co. stock logo
CYAN
Cyanotech
0.12
1.00
0.30
JAN stock logo
JAN
JAN
N/AN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
1.02
1.30
1.06
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
N/A
10.02
10.03

Institutional Ownership

CompanyInstitutional Ownership
Cyanotech Co. stock logo
CYAN
Cyanotech
24.40%
JAN stock logo
JAN
JAN
6.27%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
12.80%

Insider Ownership

CompanyInsider Ownership
Cyanotech Co. stock logo
CYAN
Cyanotech
34.40%
JAN stock logo
JAN
JAN
3.00%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.17%
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
4.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cyanotech Co. stock logo
CYAN
Cyanotech
957.39 million4.85 millionNot Optionable
JAN stock logo
JAN
JAN
N/A263.14 millionN/AN/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
75,0002.47 billion2.47 billionOptionable
Revelation Biosciences, Inc. stock logo
REVB
Revelation Biosciences
103.91 million3.72 millionNot Optionable

Recent News About These Companies

REVB Poised for Big Year
REVB Comes to Agreement with FDA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cyanotech stock logo

Cyanotech OTCMKTS:CYAN

$0.52 0.00 (-0.02%)
As of 09:30 AM Eastern

Cyanotech Corp. engages in the cultivation, production, and sale of natural products derived from microalgae for the health and human nutrition markets worldwide. Its products include BioAstin Hawaiian Astaxanthin, a dietary antioxidant, which is used as a human dietary supplement and dietary ingredient to support and maintain the body's natural inflammatory response, enhance skin, and support eye, joint, and immune health; and Hawaiian Spirulina Pacifica, a nutrient-rich dietary supplement that is used for extra energy, a strengthened immune system, cardiovascular benefits, and as a source of antioxidant carotenoids. The company was founded by Gerald R. Cysewski in 1983 and is headquartered in Kailua-Kona, HI.

JAN stock logo

JAN NYSE:JAN

$26.58 -0.19 (-0.69%)
As of 01:41 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Upon completion of this offering, we will be the only U.S. publicly traded REIT focused exclusively on the senior housing sector and the only U.S. publicly traded REIT whose entire portfolio is owned and operated under RIDEA structures. We have an initial portfolio consisting of 34 senior housing communities, comprised of 10,422 units as of December 31, 2025. Our communities are located primarily in major retirement markets across 10 states, with units in Florida and Texas representing 69% of the total units as of December 31, 2025. All of our communities are owned and operated under RIDEA structures. Services provided by our operators under a RIDEA structure are primarily paid for directly by the residents, rather than governmental reimbursement programs, which provides us with greater visibility into operating cash flow from our communities. We will be externally managed by Healthpeak Investment Management, LLC, an indirect subsidiary of Healthpeak, which will be our largest stockholder following the completion of this offering and the formation transactions. Healthpeak is an S&P 500 REIT that invests in and manages real estate focused on healthcare discovery and delivery in the United States. Although our Manager was recently formed, Healthpeak has been a public company and an active investor in healthcare real estate for over 40 years. Healthpeak has an extensive network for sourcing and managing senior housing investments that it has established over its long operating history, and we will benefit from this network through our Manager. Our initial portfolio reflects our commitment to delivering sustainable growth through differentiated senior housing solutions and strategic collaborations with high quality operators. We intend to focus exclusively on the senior housing sector because we believe that favorable demographic trends will enable us to create long-term value for our stockholders. We intend to grow our initial portfolio by drawing on our Manager’s origination and sourcing capabilities and established relationships to execute on attractive investment opportunities in the senior housing sector. Of the 34 senior housing communities in our initial portfolio, we describe 15 of these communities, comprising an aggregate of 7,067 units as of December 31, 2025, as “life plan communities.” Life plan communities are a form of senior housing that offer a full continuum of care, including independent living, assisted living, memory care, and skilled nursing, in large-scale communities. Life plan communities differ from other housing and care options for seniors because they typically operate under an entrance fee model, which requires a one-time entrance fee in addition to monthly resident fees, and offer integrated housing, activities, services, and healthcare benefits on a single campus. Life plan communities are designed for individuals and couples seeking an active lifestyle where they can avoid moving a second or third time as they age, and most entrance fee contracts include some level of discounted rates on future healthcare. Compared to traditional rental senior housing, life plan communities offer resident-driven decision making, lifestyle choice, peace of mind from continuum of care, and larger units, with most of our independent living units averaging approximately 1,100 square feet. Residents typically enter our life plan communities in good health in their late 70s or early 80s and stay for eight to ten years — substantially longer than in traditional rental senior housing — supporting stable occupancy and predictable cash flows. The large size of our life plan community campuses, spanning 48 acres of land on average and consisting of approximately 471 units on average as of December 31, 2025, allows us to offer more substantial indoor and outdoor amenities to provide a highly active social life for seniors and create a differentiated senior housing product with high barriers to entry. Due to sizeable land needs, high development costs, financing challenges and pre-leasing requirements, new supply of life plan communities is very low, thereby enabling favorable supply and demand fundamentals for incumbents. We believe life plan communities exhibit consistently resilient occupancy, positioning them as a business with embedded operating leverage and growth visibility, which in turn can provide strong risk-adjusted returns. The other 19 senior housing communities in our initial portfolio, comprising an aggregate of 3,355 units as of December 31, 2025, are primarily independent living, with certain communities offering assisted living, memory care, and/or skilled nursing. These communities are often amenitized, apartment-like buildings with private residences ranging from studios to large apartments. We were formed in December 2025. Our principal executive office is located in Denver, CO.

Merck & Co., Inc. stock logo

Merck & Co., Inc. NYSE:MRK

$121.87 +5.99 (+5.17%)
As of 01:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Revelation Biosciences stock logo

Revelation Biosciences NASDAQ:REVB

$1.07 -0.01 (-0.93%)
As of 01:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.